Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Analysts at Svb Leerink lifted their FY2020 earnings estimates for shares of Alexion Pharmaceuticals in a research note issued on Tuesday, July 16th. Svb Leerink analyst now forecasts that the biopharmaceutical company will post earnings per share of $11.35 for the year, up from their prior forecast of $11.30.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.68 earnings per share.
Shares of ALXN stock opened at $123.26 on Wednesday. The firm has a market capitalization of $27.54 billion, a PE ratio of 17.39, a price-to-earnings-growth ratio of 0.92 and a beta of 1.64. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The firm’s 50 day simple moving average is $123.54.
In related news, Director Bros. Advisors Lp Baker sold 300,000 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $123.74, for a total value of $37,122,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the sale, the executive vice president now owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. Insiders have sold 428,567 shares of company stock worth $53,420,869 in the last quarter. Insiders own 4.08% of the company’s stock.
Large investors have recently modified their holdings of the stock. Vigilant Capital Management LLC increased its stake in Alexion Pharmaceuticals by 4.1% during the second quarter. Vigilant Capital Management LLC now owns 113,829 shares of the biopharmaceutical company’s stock valued at $14,909,000 after purchasing an additional 4,467 shares during the last quarter. Bank of The West increased its stake in Alexion Pharmaceuticals by 4.1% during the second quarter. Bank of The West now owns 34,841 shares of the biopharmaceutical company’s stock valued at $4,563,000 after purchasing an additional 1,384 shares during the last quarter. Oakbrook Investments LLC bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $1,601,000. Fox Run Management L.L.C. bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $604,000. Finally, NEXT Financial Group Inc bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $36,000. Institutional investors and hedge funds own 94.74% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.